Evofem Biosciences (EVFM) Misses Q1 EPS by 8c

Evofem Biosciences (NASDAQ: EVFM) reported Q1 EPS of ($0.40), $0.08 worse than the analyst estimate of ($0.32).

"We are now less than three weeks away from the PDUFA date for Phexxi™ and the potential to deliver the first non-hormonal contraceptive innovation in decades. We are encouraged by our ongoing discussions with the FDA regarding the potential label for Phexxi and we look forward to sharing more details about our unique Phexxi TeleContraception™ platform and other launch initiatives on today's call," said Saundra Pelletier, Evofem's Chief Executive Officer.

"Our recent strategic financing agreement for up to $25 million, coupled with our disciplined approach to resource allocation, gives us the financial flexibility we need to ensure that Phexxi gets the launch it deserves. If approved, we plan to launch Phexxi in early September along with a robust offering of support services designed to facilitate access to Phexxi and establish Evofem as a leader in women's health."

For earnings history and earnings-related data on Evofem Biosciences (EVFM) click here.

You May Also Be Interested In

• Nanometrics (NANO) Issues Business Update, Reports FY23 Results
• Colony Bankcorp (CBAN) Tops Q1 EPS by 2c
• Empire State Realty Trust (ESRT) Reports Q1 EPS of $0.03